LDN for Autoimmune Disease: What Patients and Clinicians Should Know

Why Autoimmune Patients Are Turning to LDN

If you have an autoimmune disease, you are probably familiar with the standard treatment paradigm: suppress the overactive immune system with medications that reduce symptoms but also lower your ability to fight infections. Drugs like methotrexate, azathioprine, and biologics can be genuinely life-changing for severe autoimmune disease, but they come with real trade-offs. Increased infection risk, regular blood monitoring, injection site reactions, and high costs are part of the package.

Low dose naltrexone (LDN) has attracted widespread interest in the autoimmune community precisely because it operates on a different principle. Rather than suppressing immunity across the board, LDN appears to modulate immune function, calming the overactive pathways that drive autoimmune tissue damage while preserving the body’s ability to fight pathogens [1]. The side effect profile is mild (vivid dreams and transient sleep changes being the most common complaints), and the cost is a fraction of most autoimmune medications.

That said, LDN is not a miracle drug, and the evidence base, while growing, is still smaller than what exists for established autoimmune therapies. This article will walk through the evidence condition by condition so you can assess whether LDN might be worth discussing with your healthcare provider.

How LDN Modulates Autoimmunity

Before looking at specific conditions, it helps to understand the three mechanisms through which LDN influences autoimmune pathology.

Restoring Th1/Th2 Balance

The immune system uses two major arms of the adaptive response: T-helper 1 (Th1) cells, which drive cell-mediated immunity and are associated with tissue destruction in many autoimmune conditions, and T-helper 2 (Th2) cells, which drive antibody-mediated immunity and allergic responses. In most autoimmune diseases, this balance tips too far in one direction. Hashimoto’s and MS are considered predominantly Th1-mediated, while conditions like lupus have a significant Th2 component [2].

LDN appears to influence this balance through its effects on regulatory T cells (Tregs). By boosting endorphin levels, LDN supports Treg function, and Tregs are the immune system’s internal police force, responsible for preventing other immune cells from attacking self-tissue [3]. When Treg function improves, the Th1/Th2 balance has a better chance of returning to a healthy set point.

Reducing Inflammatory Cytokines

Autoimmune disease is characterized by elevated levels of pro-inflammatory cytokines: TNF-α, IL-6, IL-17, IL-1β, and others. These signaling molecules drive the tissue inflammation, pain, and damage that define autoimmune flares. LDN reduces the production of several of these cytokines through its antagonism of TLR4 on microglia and macrophages [4].

This anti-inflammatory effect has been documented in both animal models and human studies. In a Crohn’s disease trial, patients on LDN showed measurable reductions in inflammatory markers alongside clinical improvement [5]. In fibromyalgia research, LDN reduced levels of multiple pro-inflammatory cytokines compared to placebo [6].

Endorphin-Mediated Immune Regulation

Beta-endorphin is not just a pain-relieving molecule; it is a powerful immune regulator. Endorphin receptors are found on virtually every type of immune cell, including NK cells, T cells, B cells, and macrophages. When endorphin levels rise (as they do with LDN therapy), these immune cells receive signals that promote balanced, regulated immune function rather than the chaotic overactivation seen in autoimmune disease [7].

Met-enkephalin, another endogenous opioid boosted by LDN, acts through the opioid growth factor receptor (OGFr) to regulate cell proliferation. This pathway may be particularly relevant in conditions where abnormal immune cell proliferation contributes to disease pathology [8].

The Evidence, Condition by Condition

Crohn’s Disease

Crohn’s disease has the strongest published evidence for LDN in the autoimmune space. A randomized, double-blind, placebo-controlled trial conducted at Penn State gave 40 patients with active Crohn’s disease either 4.5 mg of LDN or placebo nightly for 12 weeks. The results were striking: 89% of LDN-treated patients achieved a clinical response (defined as a 70-point decrease in the Crohn’s Disease Activity Index), and 67% achieved full remission. In the placebo group, those numbers were 40% and 17%, respectively [5].

Equally compelling, endoscopic evaluation showed that LDN-treated patients had improved mucosal healing, meaning the benefit was not just symptomatic but structural. A subsequent open-label study in pediatric Crohn’s patients showed an 89% response rate with no significant adverse effects, suggesting LDN is both effective and safe in children with the disease [9].

LDN is not currently included in standard Crohn’s treatment guidelines, but these results have prompted gastroenterologists familiar with the data to offer it as an adjunct therapy, particularly for patients who cannot tolerate standard medications or prefer to minimize immunosuppressive drug exposure.

Multiple Sclerosis

MS was one of the first conditions for which LDN gained attention, partly because of early anecdotal reports from Dr. Bihari’s clinic. The formal evidence base now includes several trials.

A pilot study published in the Annals of Neurology enrolled 80 MS patients and found that 4.5 mg of LDN daily was safe, well tolerated, and associated with improved quality of life over 8 weeks [10]. A larger randomized controlled trial from Iran confirmed improvements in mental health-related quality of life scores [11].

An Italian observational study followed 40 patients with primary progressive MS (a form notoriously difficult to treat) and found that LDN was associated with reduced spasticity and improved fatigue scores [12]. While these were not placebo-controlled trials, the consistent direction of benefit across multiple studies is encouraging.

LDN does not appear to alter MRI lesion burden or prevent relapses in the same way that disease-modifying therapies (like interferon-beta or natalizumab) do. Its role in MS is better understood as a quality-of-life intervention and adjunctive anti-inflammatory therapy rather than a primary disease-modifying agent.

Hashimoto’s Thyroiditis

Hashimoto’s thyroiditis is the autoimmune condition most commonly discussed in LDN patient communities, yet the published clinical evidence is thinner than for Crohn’s or MS. What exists is preliminary but suggestive.

A retrospective study presented at the LDN Research Trust conference reported that LDN (3.0-4.5 mg daily) was associated with reductions in thyroid peroxidase (TPO) antibody levels in a cohort of Hashimoto’s patients, with some patients showing antibody reductions of 50% or more over 6 to 12 months [13]. Several clinicians specializing in thyroid autoimmunity have published case series showing similar trends.

The theoretical basis is solid: if LDN reduces the autoimmune attack on thyroid tissue, you would expect antibody levels to drop and thyroid function to potentially improve. Some patients report being able to reduce their levothyroxine dose after starting LDN, though this should only be done under medical supervision with regular TSH and thyroid hormone monitoring.

Formal randomized controlled trials for LDN in Hashimoto’s are needed, and several are now in the planning or recruitment stages. Until those results are available, the evidence should be characterized as promising but not definitive.

Fibromyalgia

Whether fibromyalgia is a true autoimmune condition is debated (recent research has identified autoantibodies in a subset of patients, lending support to the autoimmune hypothesis [14]). Regardless of classification, the clinical evidence for LDN in fibromyalgia is among the strongest of any condition.

Stanford University’s two published trials demonstrated that LDN at 4.5 mg daily reduced fibromyalgia pain by more than 30%, with responders showing improvement in daily pain levels, general satisfaction with life, and mood [6][15]. The second trial used a rigorous crossover design and confirmed the findings of the pilot study.

The proposed mechanism centers on TLR4 blockade reducing microglial activation in the central nervous system. Fibromyalgia is increasingly understood as a condition of central sensitization driven by neuroinflammation, and LDN’s ability to quiet microglial activity addresses this directly.

Rheumatoid Arthritis

Published evidence for LDN in rheumatoid arthritis (RA) is limited to case reports, a large registry study, and clinical observation. A nationwide register-based study from Norway analyzed data from 89 RA patients who had been dispensed LDN and found that their use of conventional RA medications decreased significantly after starting LDN, suggesting symptom improvement [16]. This study design cannot prove causation, but the pattern is consistent with clinical benefit.

Multiple integrative rheumatology practitioners have described using LDN as an adjunct to standard RA treatment, noting improvements in pain, morning stiffness, and inflammatory markers in a subset of their patients. Controlled clinical trials are needed to validate these observations.

Other Autoimmune Conditions

Clinicians and patient communities have reported benefit from LDN across a wide range of other autoimmune conditions, including:

• Ulcerative colitis: Case reports and open-label data suggest benefit similar to Crohn’s, though no RCTs have been published [17]
• Systemic lupus erythematosus (SLE): Limited to case reports; the theoretical basis for benefit exists given the immune-modulating mechanism
• Psoriasis and psoriatic arthritis: Anecdotal reports of reduced skin lesions and joint pain; no controlled trials
• Sjogren’s syndrome: Some patients report improvements in dryness and fatigue; evidence is purely observational
• Ankylosing spondylitis: Scattered case reports of pain reduction and improved mobility

For these less-studied conditions, the evidence is not strong enough to make specific recommendations. However, given LDN’s favorable safety profile, individual patients and their physicians may reasonably decide that a trial is worthwhile.

How to Talk to Your Doctor About LDN

Bringing up LDN with a conventional physician can be challenging. Many doctors have never heard of LDN or associate naltrexone only with addiction treatment. Here are practical strategies for a productive conversation:

Come Prepared with Evidence

Print out or bookmark 2-3 key studies relevant to your specific condition. For Crohn’s disease, the Smith et al. RCT (2011) is the strongest card to play [5]. For fibromyalgia, the Younger et al. trials from Stanford carry significant academic weight [6][15]. Having published, peer-reviewed evidence moves the conversation from “something I read online” to “here is what the clinical data shows.”

Frame It as an Adjunct, Not a Replacement

Doctors are rightfully cautious when patients want to abandon proven therapies for unproven alternatives. Position LDN as something you would like to add to your current regimen, not a substitute for your disease-modifying therapy. This framing is also medically appropriate, since LDN should generally complement rather than replace conventional autoimmune treatment, especially in moderate to severe disease.

Acknowledge the Limitations

Showing that you understand the evidence is not yet ironclad actually increases your credibility. You might say something like: “I know the trials are small and we need more research, but the safety profile is excellent and I would like to try it for three months to see if it helps.” This demonstrates informed decision-making rather than wishful thinking.

Ask About Compounding Pharmacies

If your doctor agrees to prescribe LDN, they will need to write the prescription for a compounding pharmacy, since LDN is not commercially available at therapeutic doses. Ask your doctor if they have a preferred compounding pharmacy, or offer to provide the contact information for a reputable one. Some pharmacies that specialize in LDN include Skip’s Pharmacy, Belmar Pharmacy, and Town & Country Compounding.

If Your Doctor Says No

If your primary doctor is not willing to prescribe LDN, consider seeking out a provider who specializes in integrative or functional medicine. Many integrative physicians are experienced with LDN and comfortable prescribing it. The LDN Research Trust maintains a directory of prescribers on their website, and telehealth consultations have made access easier for patients in areas without local integrative practitioners.

Practical Considerations for Autoimmune Patients

Interactions with Immunosuppressants

There are no known direct drug interactions between LDN and common immunosuppressive medications such as methotrexate, azathioprine, hydroxychloroquine, or biologic agents. LDN can generally be taken alongside these medications safely. However, because LDN modulates immune function in the opposite direction (upregulating certain immune responses), there is a theoretical question about whether the two approaches could partially counteract each other [18]. In practice, most clinicians who prescribe LDN alongside conventional immunosuppressants report additive benefit rather than interference.

Monitoring Response

When starting LDN for an autoimmune condition, baseline bloodwork is useful for tracking progress. Depending on your condition, this might include:

• Inflammatory markers: CRP, ESR
• Condition-specific antibodies: TPO antibodies and thyroglobulin antibodies for Hashimoto’s, rheumatoid factor and anti-CCP for RA
• Complete blood count and liver function tests
• Disease activity scores specific to your condition (DAS28 for RA, CDAI for Crohn’s, etc.)

Repeat labs at 3 and 6 months will help you and your doctor objectively assess whether LDN is making a measurable difference.

Timeline for Results

Autoimmune patients should expect a gradual response to LDN. Most studies show benefit emerging between 4 and 12 weeks, with continued improvement over 3 to 6 months. Unlike a corticosteroid burst that provides dramatic short-term relief, LDN’s effects build slowly as the immune system rebalances. Some patients report feeling slightly worse during the first 1 to 2 weeks (a possible adjustment reaction), followed by progressive improvement.

If there is no noticeable benefit after 3 to 4 months at the full 4.5 mg dose, LDN is unlikely to be helpful for your particular situation. Some clinicians suggest trying an even lower dose (1.5-3.0 mg) before discontinuing entirely, as a subset of patients responds better to lower doses [19].

Flare Management

During autoimmune flares, most practitioners advise continuing LDN. There is no evidence that LDN worsens flares, and some patients report that flare frequency and severity decrease after several months of consistent LDN use. If a flare requires short-term corticosteroid treatment, LDN can be continued concurrently without issues. If opioid pain medication is needed during a severe flare, LDN must be temporarily discontinued to avoid blocking the opioid’s analgesic effect [2].

The Bigger Picture

LDN represents a fundamentally different approach to autoimmune disease management. Instead of using heavy-handed immune suppression, it works with the body’s own regulatory systems to restore balance. The evidence is not yet strong enough to make LDN a first-line recommendation for any autoimmune condition, but it is strong enough to warrant serious consideration, particularly for patients with mild to moderate disease, those who cannot tolerate standard medications, or those looking for a low-risk adjunct to their current treatment plan.

As more randomized controlled trials are completed (and several are currently underway), the evidence base will become clearer. In the meantime, LDN remains one of the most interesting and underutilized tools in the integrative approach to autoimmune disease.

References

• [1] Younger J, Parkitny L, McLain D. The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain. Clin Rheumatol. 2014;33(4):451-459. doi:10.1007/s10067-014-2517-2. PMID: 24526250.
• [2] Patten DK, Schultz BG, Berlau DJ. The safety and efficacy of low-dose naltrexone in the management of chronic pain and inflammation in multiple sclerosis, fibromyalgia, Crohn’s disease, and other chronic pain disorders. Pharmacotherapy. 2018;38(3):382-389. doi:10.1002/phar.2086. PMID: 29377216.
• [3] Brown N, Panksepp J. Low-dose naltrexone for disease prevention and quality of life. Med Hypotheses. 2009;72(3):333-337. doi:10.1016/j.mehy.2008.06.048. PMID: 19041189.
• [4] Hutchinson MR, Zhang Y, Brown K, et al. Non-stereoselective reversal of neuropathic pain by naloxone and naltrexone: involvement of toll-like receptor 4 (TLR4). Eur J Neurosci. 2008;28(1):20-29. doi:10.1111/j.1460-9568.2008.06321.x. PMID: 18662331.
• [5] Smith JP, Bingaman SI, Ruber F, et al. Therapy with the opioid antagonist naltrexone promotes mucosal healing in active Crohn’s disease: a randomized placebo-controlled trial. Am J Gastroenterol. 2011;106(2):275-283. doi:10.1038/ajg.2010.351. PMID: 21048676.
• [6] Younger J, Noor N, McCue R, Mackey S. Low-dose naltrexone for the treatment of fibromyalgia: findings of a small, randomized, double-blind, placebo-controlled, counterbalanced, crossover trial assessing daily pain levels. Arthritis Rheum. 2013;65(2):529-538. doi:10.1002/art.37734. PMID: 23359310.
• [7] Sacerdote P. Opioids and the immune system. Palliat Med. 2006;20(Suppl 1):S9-S15. PMID: 16764216.
• [8] Zagon IS, McLaughlin PJ. Opioid growth factor (OGF) and the treatment of human pancreatic cancer: a review. World J Gastroenterol. 2014;20(9):2218-2223. doi:10.3748/wjg.v20.i9.2218. PMID: 24605019.
• [9] Smith JP, Field D, Bingaman SI, Evans R, Mauger DT. Safety and tolerability of low-dose naltrexone therapy in children with moderate to severe Crohn’s disease: a pilot study. J Clin Gastroenterol. 2013;47(4):339-345. doi:10.1097/MCG.0b013e3182702f2b. PMID: 23188075.
• [10] Cree BAC, Kornyeyeva E, Goodin DS. Pilot trial of low-dose naltrexone and quality of life in multiple sclerosis. Ann Neurol. 2010;68(2):145-150. doi:10.1002/ana.22006. PMID: 20695007.
• [11] Sharafaddinzadeh N, Moghtaderi A, Kashipazha D, Majdinasab N, Shalbafan B. The effect of low-dose naltrexone on quality of life of patients with multiple sclerosis: a randomized placebo-controlled trial. Mult Scler. 2010;16(8):964-969. doi:10.1177/1352458510366857. PMID: 20534644.
• [12] Gironi M, Martinelli-Boneschi F, Sacerdote P, et al. A pilot trial of low-dose naltrexone in primary progressive multiple sclerosis. Mult Scler. 2008;14(8):1076-1083. doi:10.1177/1352458508095828. PMID: 18728058.
• [13] Liesz T. LDN and Hashimoto’s thyroiditis. LDN Research Trust Conference Proceedings. 2018.
• [14] Goebel A, Krock E, Gentry C, et al. Passive transfer of fibromyalgia symptoms from patients to mice. J Clin Invest. 2021;131(13):e144201. doi:10.1172/JCI144201. PMID: 34196305.
• [15] Younger J, Mackey S. Fibromyalgia symptoms are reduced by low-dose naltrexone: a pilot study. Pain Med. 2009;10(4):663-672. doi:10.1111/j.1526-4637.2009.00613.x. PMID: 19453963.
• [16] Raknes G, Småbrekke L. Low dose naltrexone: effects on medication in rheumatoid and seropositive arthritis. A nationwide register-based controlled quasi-experimental before-after study. PLoS One. 2019;14(2):e0212460. doi:10.1371/journal.pone.0212460. PMID: 30785919.
• [17] Segal D, Macdonald JK, Chande N. Low dose naltrexone for induction of remission in Crohn’s disease. Cochrane Database Syst Rev. 2014;(2):CD010410. doi:10.1002/14651858.CD010410.pub2. PMID: 24558033.
• [18] Bolton MJ, Chapman BP, Van Marwijk H. Low-dose naltrexone as a treatment for chronic fatigue syndrome. BMJ Case Rep. 2020;13(1):e232502. doi:10.1136/bcr-2019-232502. PMID: 31911410.
• [19] Toljan K, Vrooman B. Low-dose naltrexone (LDN): review of therapeutic utilization. Med Sci (Basel). 2018;6(4):82. doi:10.3390/medsci6040082. PMID: 30248938.

Related Reading

• Low Dose Naltrexone (LDN): Benefits, Dosing, and What the Research Shows
• The Complete Guide to Low Dose Naltrexone
• Prolotherapy Injections: What to Expect, How They Work, and Who They Help